Samsung BioLogics
Samsung Biologics, founded in April 2011 and headquartered in Incheon, South Korea, is a leading contract development and manufacturing organization (CDMO) in the biopharmaceutical industry. Established by key players within the Samsung Group and Quintiles Transnational Corp, the company aims to provide high-quality, innovative, and efficient services to its global clients, with Europe and the United States accounting for 90% of its revenue. Samsung Biologics offers comprehensive development and manufacturing services, spanning from cell line development to final commercial production, and boasts a total production capacity of 604,000 liters, one of the largest worldwide. The company's CDMO services represent 72.4% of its revenue, while the remainder comes from its subsidiary, Samsung Bioepis, which focuses on developing and manufacturing biosimilars. The organization emphasizes strict adherence to quality and regulatory standards, ensuring compliance with international cGMP requirements. Dr. Tae Han Kim, the Chief Executive Officer, has played a significant role in the company’s expansion and operational excellence since joining Samsung in 1979.
Top Stages
2 past transactions
C2N Diagnostics
Corporate Round in 2025
C2N Diagnostics, LLC is a privately held company focused on the development of protein diagnostics and therapeutics targeting progressive neurodegeneration, particularly Alzheimer's disease. Founded in 2007 by Drs. David Holtzman and Randall Bateman from Washington University School of Medicine, along with LifeTech Research, the company operates from the Center for Emerging Technologies in St. Louis. C2N Diagnostics specializes in mass spectrometry-based techniques that allow for the precise identification, quantification, and monitoring of proteins and biomolecules associated with neurological disorders. By providing accurate and sensitive diagnostics, the company aims to enhance the detection and characterization of neurocognitive disorders, ultimately supporting improved patient care and treatment strategies.
Samsung Bioepis
Acquisition in 2022
Samsung Bioepis Co., Ltd. is a biopharmaceutical company based in Incheon, South Korea, specializing in the development and production of biosimilar products. Established in 2012, the company aims to enhance patient access to high-quality treatment options through its extensive pipeline of biosimilar candidates. Samsung Bioepis focuses on innovative therapies targeting various health conditions, including neurodegenerative diseases, hemophilia, and autoimmune disorders. The company has formed a strategic collaboration with Takeda Pharmaceutical Company, further strengthening its position in the biopharmaceutical industry. By leveraging process innovation, Samsung Bioepis strives to provide improved healthcare solutions for patients worldwide.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.